Clinical Trials Logo
  1. Home
  2. Tumors
  3. NCT00372437

A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine

Tumors Clinical Trial

Official title:
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine

Clinical Trial Summary

Inthis study, MGCD0103, a new anticancer drug under investigation, is given three times weekly in combination with gemcitabine to patients with solid tumours.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00372437
Study type Interventional
Source Mirati Therapeutics Inc.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date September 2006
Completion date December 2008
View Details
See also
  Status Clinical Trial Phase
Suspended NCT01562626 - Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors Phase 1/Phase 2
Completed NCT00435669 - A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664) Phase 1
Completed NCT00400023 - A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors Phase 1
Completed NCT00410696 - Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy Phase 2
Completed NCT00395434 - Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors Phase 1
Completed NCT00375245 - Rapamycin With Grapefruit Juice for Advanced Malignancies Phase 1
Recruiting NCT00553033 - Laparoscopic Liver Resection N/A
Completed NCT00248404 - NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS) Phase 1/Phase 2
Completed NCT00222443 - Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy Phase 1
Completed NCT00207103 - MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors Phase 1
Terminated NCT03251924 - A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05103969 - Cohort of Tumors With POLE/D1 Mutation
Completed NCT00446446 - PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) Phase 2
Completed NCT02275910 - Phase 1 Study of E7090 in Subjects With Solid Tumor Phase 1
Terminated NCT02271516 - to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage Phase 1
Completed NCT01448759 - Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel N/A
Terminated NCT01081808 - Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors Phase 1
Completed NCT00398814 - Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers Phase 1
Completed NCT00389480 - Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies Phase 1
Terminated NCT00130936 - Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates Phase 1/Phase 2